Srikanth Radhakrishnan Sells 14,245 Shares of Pulmonx (NASDAQ:LUNG) Stock

Pulmonx Corporation (NASDAQ:LUNG) insider Srikanth Radhakrishnan sold 14,245 shares of the stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $2.26, for a total transaction of $32,193.70. Following the transaction, the insider owned 316,994 shares of the company’s stock, valued at $716,406.44. This represents a 4.30% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Pulmonx Price Performance

LUNG opened at $2.21 on Friday. The firm has a 50-day moving average price of $1.82 and a 200-day moving average price of $1.57. Pulmonx Corporation has a twelve month low of $1.13 and a twelve month high of $2.89. The company has a quick ratio of 3.52, a current ratio of 4.32 and a debt-to-equity ratio of 0.95. The company has a market capitalization of $94.92 million, a price-to-earnings ratio of -1.91 and a beta of 0.34.

Pulmonx (NASDAQ:LUNG) last released its quarterly earnings data on Wednesday, July 29th. The company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.04. The company had revenue of $22.76 million during the quarter, compared to the consensus estimate of $22.39 million. Pulmonx had a negative net margin of 55.03% and a negative return on equity of 96.66%. Equities analysts expect that Pulmonx Corporation will post -1.05 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. Wall Street Zen upgraded Pulmonx from a “sell” rating to a “hold” rating in a research report on Saturday, June 27th. Weiss Ratings raised Pulmonx from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 25th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Pulmonx has an average rating of “Moderate Buy” and an average target price of $7.67.

Pulmonx News Roundup

Here are the key news stories impacting Pulmonx this week:

• Positive Sentiment: Analyst sentiment remains broadly favorable, with three Buy ratings and one Sell rating producing a “Moderate Buy” consensus. The average price target of $7.67 is substantially above recent trading levels, suggesting significant potential upside if Pulmonx delivers on its growth plans. Pulmonx analyst and earnings information
• Positive Sentiment: Pulmonx’s latest quarterly results exceeded expectations: revenue was $22.76 million versus the $22.39 million consensus estimate, while its loss of $0.24 per share was narrower than the expected $0.28 loss. Pulmonx quarterly results
• Neutral Sentiment: CEO Glendon French III, General Counsel David Lehman, Geoffrey Rose and Srikanth Radhakrishnan sold a combined 78,340 shares at approximately $2.26 per share. The filings say the transactions covered tax-withholding obligations related to vested equity awards, reducing their significance as a signal of declining confidence; however, the sales may add modest short-term supply. Pulmonx insider sales report
• Negative Sentiment: Recent gains have triggered profit-taking, contributing to the stock’s retreat and weakening short-term trading sentiment. Pulmonx shares fall following recent gains
• Negative Sentiment: Pulmonx remains unprofitable, and analysts expect a full-year loss of roughly $1.05 per share. The company’s negative margins and uncertain path to sustained profitability are keeping investors cautious despite the earnings beat. Pulmonx profit-taking and earnings outlook

Hedge Funds Weigh In On Pulmonx

Several hedge funds have recently bought and sold shares of the company. R Squared Ltd bought a new stake in Pulmonx during the 1st quarter worth approximately $26,000. Cerity Partners LLC bought a new position in Pulmonx in the 4th quarter valued at $27,000. Opal Capital LLC bought a new position in Pulmonx in the 4th quarter valued at $29,000. Jain Global LLC bought a new position in Pulmonx in the 3rd quarter valued at $30,000. Finally, Sei Investments Co. purchased a new position in shares of Pulmonx during the 1st quarter valued at $31,000. Hedge funds and other institutional investors own 91.04% of the company’s stock.

About Pulmonx

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.